Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Schering-Plough's Claritin

Executive Summary

Schering-Plough's Claritin: Loratadine syrup (10 mg per 10 mL, NDA 20-641) is approved by FDA Oct. 14 for use in patients six years of age and older. Schering touts Claritin as "the first and only nondrowsy antihistamine syrup for children"; Pfizer's antihistamine Zyrtec (cetirizine) was approved in a syrup formulation for children age six and older Sept. 27 ("The Pink Sheet" Oct. 7, In Brief). The children's dosage for Claritin is 10 mg syrup (two teaspoonsful) once daily, labeling states. The approved indication for Claritin 10 mg tablets has also been expanded to children age six and older...
UsernamePublicRestriction

Register

PS029044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel